The French biotech Abivax announced to end the clinical trial of its drug candidate against Covid-19, due to its
"lack of effectiveness"
, in a
press
release this Friday evening.
Read also: Covid-19: the government makes the biotech drug Abivax "a priority"
Called ABX464, this treatment had obtained the status of national research priority. In May 2020, he received the green light from the French regulatory authorities (ANSM) to be tested against Covid-19, during a clinical trial called “miR-AGE” which included 1,034 patients.